All In Biotech

Drug Trial Radar · NCT05775289

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Mar 15, 2023

Primary completion

Jun 20, 2024

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • TobemstomigDrug

    Participants will receive intravenous (IV) tobemstomig for four 21-day cycles

  • PembrolizumabDrug

    Participants will receive IV pembrolizumab four 21-day cycles

  • PaclitaxelDrug

    Participants will receive IV paclitaxel Q3W for four 21-day cycles

  • PemetrexedDrug

    Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity

  • CarboplatinDrug

    Participants will receive IV carboplatin Q3W for four 21-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Randomization to date of first documented disease progression or death (up to approximately 15 months)
  2. Objective Response Rate (ORR)Time frame: Up to approximately 15 months

Locations

50 sites in 11 countries. Site status is shown where the registry gives one.

  • Henry Ford Health System

    Detroit, Michigan

  • Renown Regional Medical Center Hospital

    Reno, Nevada

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Lyell McEwin Hospital

    Adelaide, South Australia, Australia

  • Barwon Health

    Geelong, Victoria, Australia

  • Monash Health

    Melbourne, Victoria, Australia

  • UZ Brussel

    Brussels, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • AZ St Maarten Campus Leopoldstr

    Mechelen, Belgium

  • Crio - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Nucleo de Oncologia da Bahia - NOB

    Salvador, Bahia, Estado de Bahia, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre X

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Centre Leon Berard

    Lyon, France

  • Hopital Cochin

    Paris, France

  • Ico Rene Gauducheau

    Saint-Herblain, France

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, France

  • Uniklinik Essen

    Essen, Germany

  • LungenClinic Großhansdorf GmbH

    Großhansdorf, Germany

  • Krankenhaus Martha-Maria Halle-Doelau

    Halle, Germany

  • Thoraxklinik Heidelberg gGmbH

    Heidelberg, Germany

  • Lungenfachklinik Immenhausen

    Immenhausen, Germany

  • Azienda Ospedaliera San Giuseppe Moscati

    Avellino, Campania, Italy

  • AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica

    Bologna, Emilia-Romagna, Italy

  • Policlinico Universitario "Agostino Gemelli"

    Rome, Lazio, Italy

  • IRCCS AOU San Martino - IST

    Genoa, Liguria, Italy

  • Irccs Istituto Europeo di Oncologia (IEO)

    Milan, Lombardy, Italy

  • Asst Di Monza

    Monza, Lombardy, Italy

  • IOV - Istituto Oncologico Veneto - IRCCS

    Padova, Veneto, Italy

  • Instituto Nacional de Cancerologia

    Distrito Federal, Mexico

  • ONCARE Viaducto Napoles

    Mexico City, Mexico CITY (federal District), Mexico

  • AMIISTO Atencion Medica Integral Investigacion y Terapia Oncologica S.A de C.V

    Mexico City, Mexico CITY (federal District), Mexico

  • Pusan National University Hospital

    Busan, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.